Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Sepracor-Looks very promising -- Ignore unavailable to you. Want to Upgrade?

To: Biomaven who wrote (2765)	5/14/1999 4:34:00 PM
From: JOEBT1	Read Replies (2) \| Respond to of 10280

Peter--The problem is that this shakes the foundations for revenue/earnings projections for SEPR. If J&J backs out, other major partners might pull out if the ICE versions are not measurably better than the existing drug. The earnings projections were made assuming a high probability of success for ICEs--J&J's action indicates a much higher risk in these projections.

To: Biomaven who wrote (2765)	5/14/1999 4:40:00 PM
From: LLCF	Respond to of 10280

Bloomberg 16:20 (update) adds analyst comment- "It's a costly market to enter because you have to give a lot of (free) samples," said Stephen Buermann, a Merrill Lynch & Co. analyst with an "accumulaate" rating on SEPR. "This could be a bump in the road for SEPR, or it could be a hill, but they'll come out of it." The competitive market, which has strong products from other large drugmakers, probably conviced J&J to drop the project, analysts said. Norastemizole, which is in P3 trails, is expected to be sumitted to the FDA by the end of next year, SEPR said. "Sepr has about 18 months, or until the drug is approved to find a new partner, Buermann said. It would probably be too expensive to market on ints own because SEPR would have to drastically expend its sales force to compete." [Beurman again] DAK